NCT03382847View on ClinicalTrials.gov

HCV Positive Heart Donors

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions
Heart Failure
Interventions
COMBINATION_PRODUCT

Transplant with HCV positive donor, followed by surveillance and treatment of viremia

Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs

Trial Locations (1)

10016

NYU Langone Transplant Institute, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03382847 - HCV Positive Heart Donors | Biotech Hunter | Biotech Hunter